Genesis Sample Clauses

Genesis. Key Places in Genesis 4 Mountains of Ararat 24 The Tower of Babel 29 Abram’s Journey to Canaan 31 Abram’s Journey to Egypt 32 Lot’s Rescue 36 Abraham’s Trip to Mount Moriah 52 Cave of Machpelah 54 Isaac’s Move to Gerar 64 Jacob’s Trip to Harran 71 Jacob’s Return to Canaan 78 Jacob’s Journey to Shechem 84 Jacob’s Journey Back to Hebron 87 Joseph Goes to Meet His Brothers 92 Jacob Moves to Egypt 112 EXODUS Key Places in Exodus 125 Moses Flees to Midian 128 Moses Returns to Egypt 134 The Exodus 151 Journey to Mount Sinai 160 LEVITICUS The Israelites at Mount Sinai 207 NUMBERS Key Places in Numbers 259 Israel’s Departure from Sinai 280 Route of the Scouts 288 Events at Kadesh 302 Events in the Wilderness 304 Battles with Sihon and Og 306 The Story of Balaam 308 Preparing to Enter the Promised Land 329 The Borders of the Promised Land 332 Cities of Refuge 334 DEUTERONOMY Events in Deuteronomy 339 The Death of Moses 401 JOSHUA Key Places in Joshua 406 Spy Mission to Jericho 410 The Battle for Ai 423 The Battle for Gibeon 427 The Battle for Hazor 430 The Conquered Land 432 The Land Yet to Be Conquered 434 The Tribes East of the Jordan 435 The Tribes West of the Jordan 442 The Cities of Refuge 446 Joshua’s Final Speech 453 JUDGES Key Places in Judges 457 Judah Fights for Its Land 460 Ehud Frees Israel from Moab 466 King Jabin Is Defeated 469 Gideon’s Battle 480 Abimelek’s Fall 484 Jephthah’s Victory 494 Samson’s Ventures 498 Samson and Delilah 502 The Tribe of Dan Moves North 506 RUTH Setting for the Story of Ruth 517 1 SAMUEL Key Places in 1 Samuel 529 The Journey to Shiloh 532 The Ark’s Travels 543 Saul Chosen as King 552 Saul Defeats the Ammonites 556 Jonathan’s Bravery 562 David and Goliath 571 David’s Escape 580 David Flees from Saul 586 Saul Chases David 594 The Battle at Gilboa 600 2 SAMUEL Key Places in 2 Samuel 604 Joab vs . Abner 610 David Defeats the Philistines 616 David’s Enemies 625 David and the Ammonites 627 Absalom’s Rebellion 641 Sheba’s Rebellion 654 1 KINGS Key Places in 1 Kings 669 Two Coronations 671 Solomon’s Kingdom 682 Solomon’s Building Projects 698 Friends and Enemies 700 The Kingdom Divides 706 Elijah Hides from Ahab 717 The Showdown at Carmel 720 Elijah Flees from Jezebel 723 God Delivers Ahab 727 2 KINGS Key Places in 2 Kings 744 War against Moab 751 The Family in Shunem 752 Elisha and the Arameans 762 Jehu Takes Over Israel 767 Israel Taken Captive 786 Israel Resettled by Foreigners 787 Judah Exiled 810 1 CHRONICLES Key Places in 1 C...
Genesis. Genesis recognizes and acknowledges that it has in the past, currently has, and prior to the Effective Time will have, access to certain confidential information of Company, such as lists of customers, operational policies, pricing and cost policies that are valuable, special and unique assets of Company and Company's business. Genesis agrees that it will not disclose any confidential information to any person, firm, corporation, association, or other entity for any purpose or reason whatsoever, prior to the Effective Time without prior written consent of Stockholder. In the event of a breach or threatened breach by Genesis of the provisions of this Section 7.12, Stockholder shall be entitled to an injunction restraining Genesis from disclosing, in whole or in part, such confidential information. Nothing contained herein shall be construed as prohibiting Stockholder from pursuing any other available remedy for such breach or threatened breach, including the recovery of damages.
Genesis. Develop, implement and evaluate GMP procedures for the large scale production of TIL suitable for infusion into patients with metastatic melanoma. - Consult with the FDA to determine the appropriate clinical trial design necessary to secure approval for the commercial development of TIL therapy for patients with metastatic melanoma and sponsor the IND for this new clinical protocol Serve as the coordinating center for the multicenter licensing clinical trial. - Supply TIL in sufficient quantities to the NCI Surgery Branch and other multicenter sites to complete the planned clinical trials (including the licensing trial) needed for FDA approval of ACT/TIL. Support the establishment of a central facility for the processing and provision of TIL for the studies under this CRADA. Surgery Branch, NCI and Genesis - Develop SOP for large scale TIL growth, selection and testing to support the FDA approval of the ACT/TIL therapy approach. Attend joint meetings with the FDA to define the exact format and criteria needed in the clinical trial(s) to obtain FDA approval. - Develop, conduct and evaluate a multiinstitutional clinical trial (to include the NCI Surgery Branch as a clinical trial site) for patients with metastatic melanoma treated with TIL that can be used as a licensing trial required for FDA approval and subsequent commercialization of ACT/TIL. PHS ICT-CRADA Case Ref. No. _______ MODEL ADOPTED June 18, 2009 - Exchange information and expertise to further the successful development of TIL therapy for patients with metastatic melanoma. Related NCI and Collaborator Agreements: None Related Intellectual Property and Business/Scientific Expertise of the Parties NCI Surgery Branch
Genesis. 11.2.1.1 Verizon will provide an appropriate EMI record to Genesis; and
Genesis. Guiding principle of all openMedicine work was to optimise health services for patients, in- clud-ing ePrescriptions and their dispensation abroad. Due to different marketing authorisa- tion pro-cedures for medicinal products, different marketing strategies of pharmaceutical companies, shortages and other factors, successfully dispensing a foreign ePrescription regularly involves identification issues, which sometimes may become complex, and requires substitution where permitted – or as an alternative a new visit to a local prescriber. Based on all earlier work, particularly the results of work-packages 2, 3, and 5, and the sum- mary discussion above, this chapter presents and elaborates the various recommendations identified by the consortium. These recommendations are intended to complement ongoing work at the level of national, European and international competent authorities and organisa- tions. The recommendations provide suggestions particularly in domains where European Un-ion issues, challenges and interests are at stake. The further development and imple- mentation of ISO IDMP by relevant players and stakeholders across the Union is mandatory for solving the core challenges around the univocal identification of medicinal products in cross-border healthcare as identified by the epSOS pilot services. The ongoing and planned eHealth service applications in the context of theConnecting Europe Facility (CEF)” initiative will benefit from the realisation of these recommendations. IDMP implementation will impact both the regulatory and clinical realms, and contribute fundamentally to improved patient safet for the citizens of Europe. Furthermore, national, Union-wide and international electronic health data interoperability will indeed become achieveable with respect to medica-tion data in ePrescriptions, ePatient Summaries, Electronic Health Records and other docu-ments and messages. Regulatory processes of registration, authorisation and marketing of new medicinal products will be streamlined across their whole life cycle, pharmacovigilance improved, and better patient information facilitated. The recommendations to follow were developed by the openMedicine team, discussed in de-tail at a two-day face-to-face meeting, presented and extensively explored with the ple- num of the expert council attached to this project at its final meeting in London in November of 2016 as well as afterwards with individual persons. They were and edited by the an edito- ...
Genesis. (g) with respect to each MSA Aircraft Asset acquired on or after the date hereof, the relevantSeller Indemnitees” (as defined in the applicable asset purchase agreement) during the period commencing on the date of delivery of such MSA Aircraft Asset and ending on the earlier of (i) the second anniversary of such date of delivery and (ii) the date of completion of the next major check in respect of such MSA Aircraft Asset. ANNEX 2 TO THE SERVICING AGREEMENT APPENDIX A TO THE SERVICING AGREEMENT CONSTRUCTION AND USAGE; DEFINITIONS

Related to Genesis

Cornerstone shall use its best efforts to register or qualify such shares under such other securities or "blue sky" laws of such jurisdictions as the LLC reasonably requests and do any and all other acts and things which may be reasonably necessary or advisable to enable the LLC to consummate the disposition in such jurisdictions of the Registered Shares (provided that Cornerstone shall not be required to (i) qualify generally to do business in any jurisdiction in which it would not otherwise be required to qualify but for this Section 6.9, (ii) subject itself to taxation in any such jurisdiction, or (iii) consent to general service of process in any such jurisdiction).
Corp has all necessary corporate power and authority to execute and deliver this Letter Agreement and each other agreement, document or writing executed or delivered in connection with the Letter Agreement and each amendment or supplement to any of the foregoing (including this Letter Agreement, the “Transaction Documents”) to which it is a party, to perform its obligations hereunder and thereunder and to consummate the transactions to which it is a party (collectively, the “Transactions”). The execution and delivery of and performance by BFE Corp. under this Letter Agreement, and the consummation by BFE Corp. of the Transactions to which it is a party, have been duly authorized and approved by all necessary corporate action by BFE Corp. (including by the Board of Directors of BFE Corp.). The Transaction Documents to which it is a party have been duly executed and delivered by BFE Corp. and, assuming due authorization, execution and delivery hereof and thereof by the other parties hereto and thereto, constitute legal, valid and binding obligations of BFE Corp., enforceable against BFE Corp. in accordance with their terms, subject to the Bankruptcy and Equity Exception.
Operating Partnership Operating Partnership shall have the meaning set forth in the preamble of this Agreement.
Millwright i. An employee shall give his employer, at the employer’s request, an up-to-date inventory of his personal tools upon his arrival at the job site. The employer may, at any time, check the accuracy of such inventory.
Asset Management Supplier will: i) maintain an asset inventory of all media and equipment where Accenture Data is stored. Access to such media and equipment will be restricted to authorized Personnel; ii) classify Accenture Data so that it is properly identified and access to it is appropriately restricted; iii) maintain an acceptable use policy with restrictions on printing Accenture Data and procedures for appropriately disposing of printed materials that contain Accenture Data when such data is no longer needed under the Agreement; iv) maintain an appropriate approval process whereby Supplier’s approval is required prior to its Personnel storing Accenture Data on portable devices, remotely accessing Accenture Data, or processing such data outside of Supplier facilities. If remote access is approved, Personnel will use multi-factor authentication, which may include the use of smart cards with certificates, One Time Password (OTP) tokens, and biometrics.
Healthcare Without limiting or being limited by any other provision of any Loan Document, Borrower has timely filed or caused to be filed all cost and other reports of every kind required under any Healthcare Laws or any provider or other agreement relating to Borrower’s participation in Medicare or Medicaid programs. Subject to subsection (a)(x) of Section 5.20, there are no claims, actions or appeals pending (and Borrower has not filed any claims or reports which could reasonably result in any such claims, actions or appeals) before any commission, board or agency or other Governmental Authority, including, without limitation, any intermediary or carrier, the Provider Reimbursement Review Board or the Administrator of the Centers for Medicare and Medicaid Services, with respect to any state or federal Medicare or Medicaid cost reports or claims filed by Borrower, or any disallowance by any commission, board or agency or other Governmental Authority in connection with any audit of such cost reports. No validation review or program integrity review related to Borrower or the consummation of the transactions contemplated herein or to the Collateral have been conducted by any commission, board or agency or other Governmental Authority in connection with the Medicare or Medicaid programs, and to the knowledge of Borrower, no such reviews are scheduled, pending or threatened against or affecting any of the providers, any of the Collateral or the consummation of the transactions contemplated hereby.
Acquisition Corp Acquisition Corp. is a wholly-owned Delaware subsidiary of Parent that was formed specifically for the purpose of the Merger and that has not conducted any business or acquired any property, and will not conduct any business or acquire any property prior to the Closing Date, except in preparation for and otherwise in connection with the transactions contemplated by the Merger Documents and the other agreements to be made pursuant to or in connection with the Merger Documents.
Comverge Comverge hereby represents and warrants the following:
Transnet (i) For legal notices: …………………………………………………… …………………………………………………… …………………………………………………… Fax No. ………… Attention: Group Legal Department
Holdings In the case of Holdings, conduct, transact or otherwise engage in any material business or operations other than the following (and activities incidental thereto): (i) its ownership of the Equity Interests of the Parent Borrower and activities incidental thereto, including payment of dividends and other amounts in respect of its Equity Interests, (ii) the maintenance of its legal existence (including the ability to incur fees, costs and expenses relating to such maintenance), (iii) the performance of its obligations with respect to the Credit Documents, the Sponsor Management Agreement and any other agreement governing Indebtedness, (iv) any public offering of its common stock or any other issuance or sale of its Equity Interests, (v) financing activities, including the issuance of securities, incurrence of indebtedness, payment of dividends, making contributions to the capital of its Subsidiaries and guaranteeing the obligations of its Subsidiaries in each case solely to the extent not prohibited hereunder; provided that with respect to the incurrence of Indebtedness, any such Indebtedness shall constitute Qualified Holding Company Debt, (vi) participating in tax, accounting and other administrative matters as a member of the consolidated group of Holdings and the Parent Borrower, (vii) holding any cash or property (but not operate any property), (viii) providing indemnification to officers and directors and (ix) activities incidental to the businesses or activities described in clauses (i) to (viii) of this Section 7.14.